- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01844180
A Phase 2, Multi-center Study to Evaluate the Efficacy and Safety of ONO-2952 in Female Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) (RESTORE)
March 17, 2016 updated by: Ono Pharma USA Inc
A Phase 2, Multi-center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ONO-2952 in Female Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)
The objective of this study is to explore efficacy, safety and tolerability of ONO-2952 in female subjects with Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D).
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
200
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Alabama
-
Anniston, Alabama, United States, 36207
- Anniston Clinical Site
-
-
Arizona
-
Goodyear, Arizona, United States, 85351
- Goodyear Clinical Site
-
Tucson, Arizona, United States, 85712
- Tucson Clinical Site
-
-
Arkansas
-
North Little Rock, Arkansas, United States, 72120
- North Little Rock Clinical Site
-
-
California
-
Carlsbad, California, United States, 92008
- Carlsbad Clinical Site
-
San Diego, California, United States, 92114
- San Diego Clinical Site
-
-
Florida
-
Boynton Beach, Florida, United States, 33426
- Boynton Beach Clinical Site
-
Clearwater, Florida, United States, 33756
- Clearwater Clinical Site
-
Deland, Florida, United States, 32720
- Deland Clinical Site
-
Hialeah, Florida, United States, 33012
- Hialeah Clinical Site
-
Lauderdale Lakes, Florida, United States, 33319
- Lauderdale Lakes Clinical Site
-
Orlando, Florida, United States, 32806
- Orlando Clinical Site
-
Port Orange, Florida, United States, 32129
- Port Orange Clinical Site
-
South Miami, Florida, United States, 33143
- South Miami Clinical Site
-
St. Petersburg, Florida, United States, 33709
- St. Petersburg Clinical Site
-
Tampa, Florida, United States, 33606
- Tampa Clinical Site
-
West Palm, Florida, United States, 33409
- West Palm Clinical Site
-
-
Illinois
-
Oak Lawn, Illinois, United States, 60453
- Oak Lawn Clinical Site
-
-
Kansas
-
Wichita, Kansas, United States, 67203
- Wichita Clinical Site
-
-
Louisiana
-
New Orleans, Louisiana, United States, 70115
- New Orleans Clinical Site
-
-
Michigan
-
Chesterfield, Michigan, United States, 48047
- Chesterfield Clincial Site
-
-
Montana
-
Billings, Montana, United States, 59102
- Billings Clinical Site
-
-
Nevada
-
Reno, Nevada, United States, 89511
- Reno Clinical Site
-
-
New Hampshire
-
Lebanon, New Hampshire, United States, 03756
- Lebanon Clinical Site
-
-
New Mexico
-
Albuquerque, New Mexico, United States, 87102
- Albuquerque Clinical Site
-
-
New York
-
Great Neck, New York, United States, 11023
- Great Neck Clinical Site
-
-
North Carolina
-
Cary, North Carolina, United States, 27518
- Cary Clinical Site
-
Highpoint, North Carolina, United States, 27262
- Highpoint Clinical Site
-
Raleigh, North Carolina, United States, 27612
- Raleigh Clinical Site
-
Winston-Salem, North Carolina, United States, 27103
- Winston-Salem Clinical Site
-
-
Ohio
-
Akron, Ohio, United States, 44311
- Akron Clinical Site
-
Columbus, Ohio, United States, 43212
- Columbus Clinical Site
-
Dayton, Ohio, United States, 45432
- Dayton Clinical Site
-
Groveport, Ohio, United States, 43125
- Groveport Clinical Site
-
Mentor, Ohio, United States, 44060
- Mentor Clinical Site
-
-
Oklahoma
-
Norman, Oklahoma, United States, 73069
- Norman Clinical Site
-
-
Pennsylvania
-
Landsdale, Pennsylvania, United States, 19446
- Lansdale Clinical Site
-
-
South Carolina
-
Greer, South Carolina, United States, 29650
- Greer Clinical Site
-
Mt. Pleasant, South Carolina, United States, 29464
- Mt. Pleasant Clinical Site
-
-
Tennessee
-
Chattanooga, Tennessee, United States, 37421
- Chattanooga Clinical Site
-
Germantown, Tennessee, United States, 38138
- Germantown Clinical Site
-
-
Texas
-
Pasadena, Texas, United States, 77505
- Pasadena Clinical Site
-
Plano, Texas, United States, 75075
- Plano Clinial Site
-
San Antonio, Texas, United States, 78229
- San Antonio Clinical Site
-
-
Utah
-
Logan, Utah, United States, 84341
- Logan Clinical Site
-
Ogden, Utah, United States, 84405
- Ogden Clinical Site
-
Salt Lake City, Utah, United States, 84107
- Salt Lake City Clinical Site
-
Sandy, Utah, United States, 84094
- Sandy Clinical Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Female 18-65 years of age (inclusive)
Diagnosed with IBS based on the following criteria (Rome III criteria):
- Symptom onset at least 6 months prior to diagnosis, and
- Recurrent abdominal pain or discomfort at least 3 days per month for the past 3 months, and
Abdominal discomfort or pain associated with two or more of the following at least 25% of the time:
- Improvement with defecation
- Onset associated with a change in frequency of stool/defecation
- Onset associated with a change in form (appearance) of stool
- Diagnosed with IBS-D, defined as loose/watery stools ≥ 25% and hard/lumpy stools ≤ 25% of defecations
Exclusion Criteria:
- Any structural abnormality of the gastrointestinal (GI) tract (other than esophagitis or gastritis)
- History of Crohn's disease, ulcerative colitis, diabetes mellitus, lactose malabsorption, malabsorption syndromes, celiac sprue, or any upper GI symptoms that may impact the assessment of IBS symptoms
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Experimental Arm 1
ONO-2952 low dose every day for 4 weeks
|
|
Experimental: Experimental Arm 2
ONO-2952 high dose every day for 4 weeks
|
|
Placebo Comparator: Placebo Arm
ONO-2952 Matching Placebo every day for 4 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Abdominal pain or stool symptoms in female subjects with IBS-D by using a numeric pain rating scale and the Bristol Stool Scale (BSS)
Time Frame: 4 weeks
|
4 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in IBS related symptoms and quality of life (QoL) by questionaire assessments
Time Frame: 4 weeks
|
4 weeks
|
Safety assessed through adverse events and clinical laboratory values
Time Frame: 4 weeks
|
4 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2013
Primary Completion (Actual)
July 1, 2014
Study Registration Dates
First Submitted
April 24, 2013
First Submitted That Met QC Criteria
April 30, 2013
First Posted (Estimate)
May 1, 2013
Study Record Updates
Last Update Posted (Estimate)
April 15, 2016
Last Update Submitted That Met QC Criteria
March 17, 2016
Last Verified
March 1, 2016
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ONO-2952POU004
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Irritable Bowel Syndrome (IBS)
-
Guy BoeckxstaensFund for Scientific Research, Flanders, BelgiumRecruiting
-
Kyle Staller, MD, MPHArdelyxRecruitingIBS - Irritable Bowel Syndrome | IBSUnited States
-
The Royal Wolverhampton Hospitals NHS TrustRecruiting
-
KU LeuvenCompletedIrritable Bowel Syndrome (IBS)Belgium, Netherlands
-
Drink PoppiCitruslabsCompletedIBS - Irritable Bowel SyndromeUnited States
-
University of HelsinkiActive, not recruitingIBS - Irritable Bowel SyndromeFinland
-
Karolinska InstitutetPraktikertjänst AB (Ltd)CompletedIBS - Irritable Bowel SyndromeSweden
-
Baylor College of MedicineNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedIrritable Bowel Syndrome (IBS)United States
-
Region SkaneCompletedIBS - Irritable Bowel SyndromeSweden
-
Baylor College of MedicineNational Institute of Nursing Research (NINR); University of WashingtonCompleted
Clinical Trials on ONO-2952
-
Ono Pharma USA IncCompleted
-
Ono Pharma USA IncCompletedHealthy Adult SubjectsUnited States
-
Ono Pharma USA IncTerminatedIrritable Bowel Syndrome (IBS)United States
-
Ono Pharma USA IncOno Pharmaceutical Co. LtdCompleted
-
Hiroshima UniversityKaneka CorporationCompleted
-
Ono Pharmaceutical Co. LtdCompleted
-
Ono Pharmaceutical Co. LtdCompletedVenous ThromboembolismUnited Kingdom
-
Ono Pharmaceutical Co. LtdCompleted
-
Ono Pharmaceutical Co. LtdTerminatedPain | Osteoarthritis, KneePoland, Hungary, Spain, Denmark, United Kingdom
-
Ono Pharmaceutical Co. LtdCompletedOsteoarthritisDenmark, United Kingdom